Gefapixant Leads to Modest Improvements in Cough
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 11, 2023 -- For adults with refractory or unexplained chronic cough, gefapixant leads to modest improvement in cough frequency, severity, and quality of life, according to a review published online Sept. 11 in the Journal of the American Medical Association to coincide with the European Respiratory Society International Congress 2023, held from Sept. 9 to 13 in Milan.
Elena Kim, from McMaster University in Hamilton, Ontario, Canada, and colleagues examined the efficacy and tolerability of gefapixant for treatment of adults with refractory or unexplained chronic cough in a systematic review of parallel and crossover randomized clinical trials (RCTs) that compared gefapixant with placebo or two or more doses of gefapixant with or without placebo. The primary analysis included nine RCTs with 2,980 patients.
The researchers found that gefapixant (45 mg twice daily) had small effects on awake cough frequency (17.6 percent reduction), cough severity (mean difference, −6.2 on 100-mm visual analog scale), and cough-specific quality of life (mean difference, 1.0 point on the Leicester Cough Questionnaire) compared with placebo. However, an important increase in treatment-related adverse events (32 more per 100 patients) and taste-related adverse events (32 more per 100 patients) was probably caused by gefapixant versus placebo. Small effects on taste-related adverse events were suggested for gefapixant (15 mg) versus placebo based on high-certainty evidence.
"Although gefapixant did appear to have a small effect on improving cough compared with placebo, the effects were marginal when compared with the large, favorable effects of placebo alone," Richard S. Irwin, M.D., and J. Mark Madison, M.D., from the University of Massachusetts Chan Medical School in Worcester, write in an accompanying editorial.
Several authors disclosed ties to pharmaceutical companies, including Merck, the manufacturer of gefapixant.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Study Addresses Nasal Rinsing and Nonkeratitis Acanthamoeba Infection
MONDAY, March 18, 2024 -- In a report published in the April issue of Emerging Infectious Diseases, the details of 10 cases of nonkeratitis Acanthamoeba infection are described...
Validated COuGH RefleX Score Can Predict Likelihood of GERD
WEDNESDAY, March 6, 2024 -- The validated Cough, Overweight/Obesity, Globus, Hiatal Hernia, Regurgitation, and Male Sex (COuGH RefluX) score can predict the likelihood of proven...
Phenylephrine Sales Sizeable and Steady Despite Efficacy Concerns
TUESDAY, Feb. 13, 2024 -- Despite concerns about clinical efficacy, phenylephrine was the most common oral decongestant sold in the United States from 2012 to 2021, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.